ESTRO37_ProgrammeBook

INTERDISCIPLINARY RADIOBIOLOGY CLINICAL BRACHYTHERAPY PHYSICS RTT YOUNG

TUESDAY 24 APRIL 2018

SYMPOSIUM Immunotherapy 11:00 - 12:15  |  ROOM 117 Non-targeted, immune-mediated effects, seem to be involved in local radiotherapy(RT) cancer treatment. RT appears to be able to autovaccinate the patient, modify the highly immunosuppressive cancer microenvironment and potentiates innate and adaptive immune responses against the tumor. Theses immunomodulatory properties of RT offer important opportunities toward the development of rational combinations with Immune Check Inhibitors (ICI), aiming to maximise local tumor control and eliminate the potential for systemic metastases. Combinations of SBRT/SRS and ICI do not seem to increase the immune-related adverse events (IRAEs) commonly involving the gut, skin, endocrine glands, liver, and lung. Chair: P.C. Lara Jimenez (Spain) Co-Chair: S. Vagge (Italy) 11:21 > Toxicity profile of immune checkpoint inhibitors and combined radiotherapy treatment Speaker: P.C. Lara Jimenez (Spain) 11:42 > Clinical Trials Development of Rational Radiotherapy and Immunotherapy Combinations: Prospects and Results Speaker: F. Herrera (Switzerland) 12:03 > Phase 1 trial of pembrolizumab with SBRT in metastatic urothelial carcinoma N. Sundahl (Belgium), S. Rottey, K. Decaestecker, P. De Visschere, D. De Maeseneer, D. Reynders, A. Meireson, E. Goetghebeur, V. Fonteyne, S. Verbeke, L. Brochez, P. Ost 11:00 > Biological basis of radioimmunotherapy Speaker: E. Deutsch (France)

SP-0679

SP-0680

SP-0681

OC-0682

Programme and Exhibition Guide | SCIENTIFIC PROGRAMME

183